Project Grant F30CA294741
Award Date
1/9/25
Completion Date
7/16/28
Dollars Obligated
$108K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This $552,968 Project Grant was awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the University of Pittsburgh to conduct research on the role of tRNA modifications in regulating gene expression and cancer stem cell biology in glioblastoma. The research aims to provide molecular insights into how metabolic control of tRNA modifications can reprogram translational programs in glioblastoma stem cells, contributing to tumor heterogeneity and treatment...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $124,548 to the University of California, Los Angeles (UCLA) to investigate the cellular and molecular mechanisms that allow glioblastoma, an aggressive brain cancer, to adapt and resist targeted therapies. The research aims to elucidate how the unique brain microenvironment drives lineage transformations in glioblastoma cells, enabling them to rapidly develop resistance to...
The federal Project Grant award, R01CA289424, was provided by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to support research aimed at characterizing the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) regulatory pathway in glioblastoma stem cells (GSCs). The $1,064,642 award, effective January 1, 2025 through December 31, 2029, will enable researchers at Tufts Medical Center to investigate how the ANG-PLXNB2-tRNA-derived small RNA (tiRNA) axis regulates GSC...
This federal Project Grant award, identified as R03NS135197, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $161,000 grant supports research to investigate the role of the connexin 43 (CX43) protein in regulating cancer stem cells in glioblastoma, the most common and deadly form of brain cancer. Specifically, the research aims to determine how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to understand the metabolic mechanisms driving the progression of glioma, a highly lethal and treatment-resistant form of brain cancer. The $682,596 award to the University of Texas Southwestern Medical Center, with a sub-award to the University of Pittsburgh, will fund a 5-year research project to investigate the role of aberrant metabolite secretion in glioma-neuron...
This federal Project Grant award, with ID R35CA283998, was awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh. The $954,000 award will support research aimed at understanding how aging promotes the growth of glioblastoma, an aggressive form of brain cancer, through both cell-autonomous mechanisms and interactions with the tumor microenvironment. The research will leverage spatial transcriptomics and metabolomics of patient tumor...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), provides $1,207,500.00 to Case Western Reserve University to develop innovative tools to capture subcellular information on RNA binding protein (RBP)-RNA interactions within living cells. The project aims to build a comprehensive spatial map of RBP-RNA interactions and explore how specific RBPs regulate the localization,...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program provides $678,879 in funding to Cold Spring Harbor Laboratory to conduct research on re-establishing tumor suppression in glioblastoma, the most common and deadly adult brain cancer. The 5-year project aims to elucidate the epigenetic mechanism by which targeting the chromatin regulator BRD8 can reactivate the p53 tumor suppressor pathway in...
This federal Project Grant award, valued at $201,172 and provided by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), aims to support research on cell-free DNA methylation patterns as a biomarker for tumor biology and clinical outcomes in glioblastoma patients. The primary goal is to develop a non-invasive method for longitudinal molecular profiling of glioblastoma, a lethal brain tumor, to improve risk stratification, clinical trial design,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center will support research on engineering mRNA-encapsulated extracellular vesicles for in vivo chimeric antigen receptor (CAR) macrophage therapy targeting glioblastoma, a highly aggressive and treatment-resistant brain cancer. The $645,873 award, effective July 5, 2024 through June 30, 2029, will fund investigations to evaluate the...